Steps Ahead in the Treatment of Advanced Colorectal Cancer: Past, Current and Possible Future Scenarios
2015; Future Medicine; Volume: 11; Issue: 19 Linguagem: Inglês
10.2217/fon.15.213
ISSN1744-8301
AutoresGiuseppe Aprile, Karim Rihawi, Mario Scartozzi, Roberto Bordonaro,
Tópico(s)Genetic factors in colorectal cancer
ResumoFuture OncologyVol. 11, No. 19 EditorialSteps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenariosGiuseppe Aprile, Karim Rihawi, Mario Scartozzi & Roberto BordonaroGiuseppe Aprile*Author for correspondence: E-mail Address: aprile.giuseppe@aoud.sanita.fvg.itDepartment of Medical Oncology, University & General Hospital, Udine, Italy, Karim RihawiDepartment of Medical Oncology, University & General Hospital, Udine, Italy, Mario ScartozziDepartment of Oncology, University Hospital, Cagliari, Italy & Roberto BordonaroOncology Department, ARNAS Garibaldi, Catania, ItalyPublished Online:11 Sep 2015https://doi.org/10.2217/fon.15.213AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antiangiogenicsclinical researchcolorectal cancerEGFR inhibitorstranslational researchReferences1 Simmonds PC. Colorectal Cancer Collaborative Group palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 321(7260), 531–535 (2000).Crossref, Medline, CAS, Google Scholar2 Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229–237 (2004).Crossref, Medline, CAS, Google Scholar3 Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25(13), 1670–1676 (2007).Crossref, Medline, CAS, Google Scholar4 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).Crossref, Medline, CAS, Google Scholar5 Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337–345 (2004).Crossref, Medline, CAS, Google Scholar6 Hecht JR, Douillard JY, Schwartzberg L et al. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat. Rev. doi: 10.1016/j.ctrv.2015.05.008 (2015) (Epub ahead of print).Crossref, Medline, Google Scholar7 Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus Irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumour KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011–2019 (2011).Crossref, Medline, CAS, Google Scholar8 Douillard JY, Siena S, Cassidy J et al. Randomized Phase III trial of Panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697–4705 (2010).Crossref, Medline, CAS, Google Scholar9 Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371(17), 1609–1618 (2014).Crossref, Medline, CAS, Google Scholar10 Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised Phase 3 trial. Lancet Oncol. 14(11), 1077–1088 (2013).Crossref, Medline, CAS, Google Scholar11 García-Alfonso P, Grande E, Polo E et al. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis 17(4), 805–821 (2014).Crossref, Medline, CAS, Google Scholar12 Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539–1544 (2007).Crossref, Medline, CAS, Google Scholar13 Van Cutsem E, Tabernero J, Lakomy R et al. Addition of Aflibercept to fluoruracil, leucovorin and irinotecan improves survival in a Phase III ramdomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin based regimen. J. Clin. Oncol. 30(28), 3499–3505 (2012).Crossref, Medline, CAS, Google Scholar14 Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin and a fluoropyrimidine (RAISE): a randomised, double-blind, multicenter, Phase 3 study. Lancet Oncol. 16(5), 499–508 (2015).Crossref, Medline, CAS, Google Scholar15 Heinemann V, von Weikestahl LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, Phase 3 trial. Lancet Oncol. 15(10), 1065–1075 (2014).Crossref, Medline, CAS, Google Scholar16 Venook A, Niedzwiecki D, Lenz HJ et al. CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab for patients w/KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum. J. Clin. Oncol. 32(5S), Abstract LBA3 (2014).Google Scholar17 Rihawi K, Giampieri R, Scartozzi M et al. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opin. Investig. Drugs 4, 1–14 (2015).Crossref, Google Scholar18 Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303–312 (2013).Crossref, Medline, CAS, Google Scholar19 Mayer RJ, Van Cutsem E, Falcone A et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372(20), 1909–1919 (2015).Crossref, Medline, Google Scholar20 Siena S, Sartore-Bianchi A, Lonardi S et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. J. Clin. Oncol. 33(Suppl.), Abstract 3508 (2015).Google Scholar21 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPrimary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice31 January 2023 | Cancers, Vol. 15, No. 3First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial19 September 2017 | British Journal of Cancer, Vol. 117, No. 8HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives12 August 2016 | Oncotarget, Vol. 7, No. 42Future Oncology: a 10-year anniversary issueNicholas J Ward & Gemma Westcott7 October 2015 | Future Oncology, Vol. 11, No. 19 Vol. 11, No. 19 STAY CONNECTED Metrics Downloaded 45 times History Published online 11 September 2015 Published in print October 2015 Information© Future Medicine LtdKeywordsantiangiogenicsclinical researchcolorectal cancerEGFR inhibitorstranslational researchFinancial & competing interests disclosureG Aprile participated in Advisory Boards or was granterd as speaker for Roche, Merck Serono, Amgen, Bayer AG, Eli Lilly and Sanofi. The authors have no other relevant affiliationsor financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materialsdiscussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)